EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.

NCT Number	NCT07698613
Lead Sponsor	Brown University Collaborators: Rakuten Medical, Inc., Rhode Island Hospital, The Miriam Hospital
Conditions	Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
Enrollment	30 participants
Start Date	2026-09
Primary Completion	2029-03 (estimated)
Study Completion	2033-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-13